

# ForPatients

by Roche

Schizophrenia

## A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02953639 BP39207

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02953639 BP39207**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years & <= 50 Years

**Healthy Volunteers**  
No

---